The Nuclear Medicine Clarification Act of 2025 directs the Nuclear Regulatory Commission to revise regulations to protect patients from unintended radiation exposure during nuclear medicine procedures. The key change is adding explicit extravasation dose thresholds to the medical-event reporting framework.
The bill also establishes a concrete implementation timeline: the regulatory revision must be completed within 120 days of enactment, and the new standards become effective 18 months after enactment. This aims to standardized how extravasation-related doses are measured and reported, strengthening patient safety oversight in nuclear imaging and therapy.
At a Glance
What It Does
The bill requires the NRC to revise 10 CFR 35.3045(a)(1) by adding a new subparagraph (iv) that defines dose thresholds for unintended exposure from extravasation during nuclear medicine procedures. It sets two concrete limits: (A) 0.5 Sv (50 rem) to the 5 cm3 tissue region receiving the highest absorbed dose, and (B) 0.5 Sv (50 rem) shallow dose to the contiguous 10 cm2 of skin receiving the highest absorbed dose, all measured during residence time.
Who It Affects
Nuclear medicine facilities, radiologists, nuclear medicine technologists, medical physicists, and hospital compliance teams will need to implement the new measurement and reporting requirements. Patients undergoing nuclear medicine procedures will be protected by standardized thresholds for extravasation-related exposure.
Why It Matters
Establishing explicit, auditable dose thresholds helps ensure that unintended exposures are consistently identified and reported as medical events. This creates a clearer accountability trail for facilities and regulators and strengthens patient safety in a domain where small exposures can have outsized consequences if not detected.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Nuclear Medicine Clarification Act of 2025 requires the Nuclear Regulatory Commission to revise its regulations to reduce the risk of unintended radiation exposure during nuclear medicine procedures. Specifically, the bill adds a new threshold to the medical-event reporting rules for doses resulting from extravasation, the leakage of radioactive material into surrounding tissue, which can occur during injections or infusions.
The new provision defines two dose-based triggers: one based on the tissue dose in a small 5 cm3 volume and another based on skin dose over a 10 cm2 area, both tied to the highest absorbed dose observed during residence time. The thresholds are set at 0.5 Sv (50 rem) for each measurement, ensuring that significant extravasation events are captured and investigated as medical events.
The amendment is limited to regulatory changes and does not by itself create new funding or broad policy changes beyond updating the CFR. The bill provides a concrete governance timeline: NRC must complete the revision within 120 days of enactment, and the revised rules take effect 18 months after enactment.
The overall aim is to standardize how these events are identified and reported, improving patient safety oversight across nuclear medicine practices.
The Five Things You Need to Know
NRC must revise 10 CFR 35.3045(a)(1) to add extravasation dose thresholds.
Thresholds: 0.5 Sv (50 rem) to 5 cm3 tissue with the highest absorbed dose.
Thresholds: 0.5 Sv (50 rem) for shallow skin dose over 10 cm2.
Implement a 18-month effective date after enactment for the new rules.
The change centers on unintended exposure during nuclear medicine and associated medical-event reporting.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the bill as the Nuclear Medicine Clarification Act of 2025. This section sets the naming convention for the statute once enacted, without altering existing regulatory structures.
Medical Event Reporting of Unintended Radiation
In subsection 2(a), the bill directs the Nuclear Regulatory Commission to revise 10 CFR 35.3045(a)(1) by adding a new paragraph (iv) that codifies dose thresholds for extravasation. The thresholds measure dose to tissue (0.5 Sv to a 5 cm3 volume with the highest absorbed dose) and dose to skin (0.5 Sv to the contiguous 10 cm2 with the highest absorbed dose) during residence time. The addition makes extravasation events meeting these thresholds reportable as medical events, standardizing how such incidents are identified and investigated.
Effective Date
The revised regulation takes effect 18 months after the date of enactment. This provides regulated entities time to implement new measurement, documentation, and reporting practices, and to align internal protocols with the updated CFR requirements.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients undergoing nuclear medicine who may experience inadvertent exposure gain clearer protection and a defined reporting process.
- Nuclear medicine clinics and hospitals that can rely on clear, auditable thresholds for incident reporting and remediation planning.
- Medical physicists and radiology compliance officers who must implement measurement and documentation practices.
- Regulators and oversight bodies gain a transparent, standardized mechanism to assess and compare medical-event reporting across facilities.
Who Bears the Cost
- Hospitals and clinics may incur costs to train staff, upgrade measurement procedures, and adjust workflows to identify and document extravasation events.
- Regulatory compliance teams may need new checklists, documentation templates, and audit processes.
- Medical supply chains and information systems may require updates to capture residence time and tumor-specific dose metrics consistently.
Key Issues
The Core Tension
Balancing rigorous patient safety with practical implementability: clear, enforceable extravasation thresholds improve safety and accountability but require consistent measurement capabilities and compliance workflows across diverse clinical settings.
The bill introduces a concrete safety mechanism for extravasation events but raises questions about measurement feasibility in all clinical environments. Facilities will need reliable methods to determine residence time, identify the exact 5 cm3 tissue volume receiving the highest dose, and measure the 10 cm2 skin area with the highest dose.
Smaller or resource-limited centers may face challenges implementing uniform documentation and reporting practices. While the 120-day window for NRC rule revision and the 18-month implementation timeline provide structure, they do not specify funding or technical assistance for compliance.
These gaps could affect how universally and promptly the thresholds are adopted in practice.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.